Nykode Therapeutics AS (OSL: NYKD)
Norway
· Delayed Price · Currency is NOK 6.44
-0.16 (-2.42%)
Aug 30, 2024, 4:25 PM CET
Nykode Therapeutics AS Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 6.15 | 12.9 | 7.17 | 33.96 | 215 | - | Upgrade
|
| Other Revenue | 0.37 | 0.42 | 1.86 | 1.8 | 0.7 | 1.41 | Upgrade
|
| Revenue | 6.52 | 13.32 | 9.03 | 35.77 | 215.7 | 1.41 | Upgrade
|
| Revenue Growth (YoY) | -49.83% | 47.56% | -74.76% | -83.42% | 15175.85% | -88.27% | Upgrade
|
| Gross Profit | 6.52 | 13.32 | 9.03 | 35.77 | 215.7 | 1.41 | Upgrade
|
| Selling, General & Admin | 31.2 | 28.42 | 18.8 | 17.51 | 16.41 | 6.2 | Upgrade
|
| Other Operating Expenses | 31.92 | 40.87 | 41.57 | 28.3 | 20.72 | 9 | Upgrade
|
| Operating Expenses | 65.37 | 71.41 | 62.19 | 46.54 | 37.43 | 15.35 | Upgrade
|
| Operating Income | -58.85 | -58.08 | -53.16 | -10.78 | 178.27 | -13.94 | Upgrade
|
| Interest Expense | -0.22 | -0.22 | -0.24 | -0.13 | -0.05 | -0.03 | Upgrade
|
| Interest & Investment Income | 8.15 | 8.95 | 3.69 | 0.27 | 0.2 | 0.39 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.12 | 5.27 | -1.24 | -0.63 | 2.63 | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | - | -0.14 | 0.03 | -0.21 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -47.81 | -44.09 | -51.09 | -11.23 | 180.84 | -13.65 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.1 | 0.12 | 0.07 | -0.05 | Upgrade
|
| Pretax Income | -47.81 | -44.09 | -50.98 | -11.12 | 180.9 | -13.7 | Upgrade
|
| Income Tax Expense | -9.89 | -8.93 | -8.24 | -1.7 | 31.13 | - | Upgrade
|
| Net Income | -37.92 | -35.15 | -42.74 | -9.41 | 149.77 | -13.7 | Upgrade
|
| Net Income to Common | -37.92 | -35.15 | -42.74 | -9.41 | 149.77 | -13.7 | Upgrade
|
| Shares Outstanding (Basic) | 320 | 301 | 290 | 286 | 280 | 273 | Upgrade
|
| Shares Outstanding (Diluted) | 320 | 301 | 290 | 286 | 296 | 293 | Upgrade
|
| Shares Change (YoY) | 17.11% | 3.59% | 1.32% | -3.31% | 1.14% | 20.80% | Upgrade
|
| EPS (Basic) | -0.12 | -0.12 | -0.15 | -0.03 | 0.54 | -0.05 | Upgrade
|
| EPS (Diluted) | -0.12 | -0.12 | -0.15 | -0.03 | 0.51 | -0.05 | Upgrade
|
| Free Cash Flow | -88.45 | -98.53 | -23.37 | 0.28 | 180.17 | -10.57 | Upgrade
|
| Free Cash Flow Per Share | -0.28 | -0.33 | -0.08 | 0.00 | 0.61 | -0.04 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -903.19% | -435.95% | -588.73% | -30.13% | 82.65% | -987.39% | Upgrade
|
| Profit Margin | -581.88% | -263.86% | -473.40% | -26.32% | 69.44% | -969.97% | Upgrade
|
| Free Cash Flow Margin | -1357.47% | -739.52% | -258.81% | 0.79% | 83.53% | -748.23% | Upgrade
|
| EBITDA | -58.14 | -57.45 | -52.74 | -10.69 | 178.3 | -13.93 | Upgrade
|
| EBITDA Margin | - | - | - | -29.89% | 82.66% | - | Upgrade
|
| D&A For EBITDA | 0.71 | 0.63 | 0.42 | 0.09 | 0.03 | 0.02 | Upgrade
|
| EBIT | -58.85 | -58.08 | -53.16 | -10.78 | 178.27 | -13.94 | Upgrade
|
| EBIT Margin | - | - | - | -30.13% | 82.65% | - | Upgrade
|
| Effective Tax Rate | - | - | - | - | 17.21% | - | Upgrade
|
| Revenue as Reported | 6.52 | 13.32 | 9.03 | 35.77 | 215.7 | 1.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.